Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have been given an average recommendation of “Hold” by the seven brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.11.
A number of equities research analysts have issued reports on ANTH shares. Jefferies Group LLC restated a “hold” rating and set a $1.75 price target (down from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th.
A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. UBS Group AG lifted its stake in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 9.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 375,989 shares of the biopharmaceutical company’s stock after buying an additional 33,901 shares during the period. UBS Group AG’s holdings in Anthera Pharmaceuticals were worth $160,000 at the end of the most recent reporting period. 27.26% of the stock is owned by hedge funds and other institutional investors.
Shares of Anthera Pharmaceuticals (ANTH) traded down 1.2256% on Thursday, hitting $1.6199. The company’s stock had a trading volume of 173,527 shares. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $2.83. The stock’s 50 day moving average price is $1.52 and its 200 day moving average price is $1.44. The stock’s market capitalization is $17.67 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.09) by $1.12. On average, analysts forecast that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Anthera Pharmaceuticals Inc (ANTH) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/10/28/anthera-pharmaceuticals-inc-anth-receives-consensus-recommendation-of-hold-from-brokerages.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.